FDA Greenlights Second CAR-T Dose in Ovarian Cancer Trial

In a novel approach, the FDA approves re-dosing a CAR-T cell therapy in ovarian cancer after initial tumor inflammation showed signs of immune engagement. A potential paradigm shift for solid tumor cell therapy.